Henry Schein, Inc. (HSIC)
Fair ValueFundamental
58
Price
$84.96
Market Cap
$9.68B
Part 1 · What the company is worth
Overview
Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as provides equipment repair services, financial services on a non-recourse basis, continuing education services for practitioners, consulting, and other services. It also markets and sells a portfolio of consumable merchandise under its own corporate brand. The Global Specialty Products segment engage in manufacturing, marketing, and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products, and other health care-related products and services. The Global Technology segment is involved in the development and distribution of practice management software, e-services, and other products which are distributed to health care providers. The company serves dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics, home health providers, and other alternate care clinics. It has a strategic partnership with GoTu Technology to help dental practices address ongoing staffing challenges. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated with artificial intelligence on September 18, 2026, shared with all users
Cited by Henry Schein as one of two national competitors in medical distribution, McKesson supplies the same office-based physicians and alternate-care sites with pharmaceuticals and medical-surgical products.
Its Medical segment distributes surgical and examination supplies to physician offices, ambulatory surgery centers and home-care providers, the same alternate-care customers Henry Schein Medical serves.
Named in Henry Schein's 10-K as its main U.S. rival, Patterson Dental sells the same consumables, equipment and practice-management software to the same dental offices, and has been privately held since Patient Square Capital took it off Nasdaq in April 2025.
The third full-service dental distributor in the United States, family-owned and unlisted, competing with Henry Schein practice by practice for the same dental supply and equipment budgets.
The other national medical competitor named in the 10-K, privately held, selling medical-surgical supplies to the same physician practices, surgery centers and long-term care facilities.
Balance Sheet & Liquidity
Revenue
$13.60B
Trailing 12 months (through 6/27/2026)
Net Income
$403M
Trailing 12 months (through 6/27/2026)
Free Cash Flow
$573M
Total Equity
$3.25B
Total Liabilities
$6.42B
Current Ratio
1.32
Interest Coverage
4.28
Debt/EBITDA
3.96
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$77.49
Current Price
$84.96
Margin of Safety
-9.6%
Fair Value Range
$54.02 - $100.96
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
24.77
ROE
12.3%
P/B Ratio
3.00
P/FCF
16.64
Gross Margin
31.3%
ROIC
6.8%
Profitability Radar
Value Creation (Economic Moat)
ROIC
6.8%
WACC
7.5%
ROIC − WACC
-0.7 pp
ROIC is roughly in line with the cost of capital — the company is barely covering its capital cost.
Fundamental Analysis Criteria
Passed (17)
- EPS shows upward trend
- ROIC 6.8%
- Gross margin 31.3%
- P/FCF 16.64
- P/B ratio 3.00
- Debt/equity ratio
- Positive free cash flow
- CapEx intensity
- Current ratio
- Interest coverage
- Debt/EBITDA
- Return on tangible assets
- ROE 12.4%
- Revenue growth 5Y 5.4%
- Earnings surprise, average 3.5%
- Earnings quality (operating cash flow / net income) 1.74
- Share dilution -4.8%
Failed (9)
- EPS CAGR 1.29%
- Price CAGR 3.64%
- Operating margin 5.0%
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Fairly Valued)
- PEG ratio 7.93
- Net margin trend 3.0% vs 3.0%
- Piotroski F-Score 4/9
Unavailable (1)
- Dividend payout –
Piotroski F-Score
Mixed signals: some areas need attention
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Buying back shares. Shareholder friendly
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Ronald N. South | Senior VP & CFO | 63 |
| Mr. Michael Saul Ettinger | Executive VP & COO | 64 |
| Mr. Mark E. Mlotek | Executive VP & Chief Strategic Officer | 69 |
| Mr. Andrea Albertini | Chief Executive Officer of Global Distribution & Technology | 55 |
| Mr. Frederick M. Lowery | CEO & Director | 54 |
| Ms. Olga Timoshkina | VP of Corporate Finance & Chief Accounting Officer | - |
| Mr. Christopher Pendergast | Senior VP & CTO | 62 |
| Mr. Graham Stanley | VP of Investor Relations & Strategic Finance Project Officer | - |
| Ms. Kelly Murphy J.D. | Senior VP & General Counsel | 44 |
| Ms. Christine Sheehy | Senior VP & Chief Human Resources Officer | 57 |
Audit Risk
4
Board Risk
8
Compensation Risk
6
Shareholder Rights Risk
4
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-02-24
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-08-04
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-10-08
via SEC EDGAR
Income History
via SEC EDGAR
Part 2 · The price and its context
This part shows how the price has behaved, not whether the company is worth owning. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Market Reaction Profile
How much HSIC moves, measured on its daily prices.
More volatile than 8% of the tracked stocks (90-day volatility).
- Volatility 30d
- 20.5%
- Volatility 90d
- 20.5%
- Beta vs S&P 500 (1y)
- 0.45Correlation 0.22
- Max drawdown (12m)
- -17.2%
- ATR (14d, % of price)
- 2.27%
Earnings reactions
How HSIC moved around its past quarterly results.
Next earnings release
Nov 3, 2026 · In 10 days · Before the open
EPS estimate: 1.36Revenue estimate: $3.5B
What usually happens
- Over the last 12 releases the stock moved a median of 3.7% the next day, up or down.
- Next-day moves: up 7, down 5 (out of 12).
- Of the 4 releases that beat estimates, the stock fell the next day after 0.
Release history
| Date | When | EPS est. | EPS actual | Surprise | Gap | 1 day | 5 days |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026 | During the session | 1.26 | 1.27 | +0.7% | +5.2% | +3.0% | +1.8% |
| May 5, 2026 | During the session | 1.24 | 1.32 | +6.3% | -0.7% | +3.3% | -4.2% |
| Feb 24, 2026 | During the session | 1.33 | 1.34 | +1.1% | +4.3% | +3.5% | +1.0% |
| Nov 4, 2025 | During the session | 1.30 | 1.38 | +5.8% | +8.3% | +10.8% | +12.9% |
| Aug 5, 2025 | During the session | n/a | n/a | n/a | -5.4% | -7.4% | -5.6% |
| May 5, 2025 | During the session | n/a | n/a | n/a | -0.4% | +2.0% | +5.1% |
| Feb 25, 2025 | During the session | n/a | n/a | n/a | +3.8% | -2.3% | -8.8% |
| Nov 5, 2024 | During the session | n/a | n/a | n/a | -1.9% | -4.6% | -5.6% |
| Aug 6, 2024 | During the session | n/a | n/a | n/a | -6.6% | -8.1% | -2.4% |
| May 7, 2024 | During the session | n/a | n/a | n/a | +3.8% | +3.9% | +6.7% |
| Feb 27, 2024 | During the session | n/a | n/a | n/a | -1.1% | -3.4% | -4.7% |
| Nov 13, 2023 | During the session | n/a | n/a | n/a | +1.2% | +5.4% | +7.3% |
Release dates from SEC 8-K filings.
Updated 10/24/2026
Historical statistics for educational purposes only. They are not forecasts and not investment advice.
Price reaction to the news
Latest news on HSIC and what the price did next.
- 6/11/2026PositiveThis Henry Schein Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
- +1 day
- 0.0%
- +3 days
- -1.2%
Return of the stock minus return of SPY over the same days. A news item close to a price move did not necessarily cause it. Historical data for educational purposes only, not investment advice.
Latest News
Recent headlines for HSIC.
- 6/11/2026POSITIVEThis Henry Schein Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Henry Schein Inc. (HSIC) has received a bullish upgrade from Wall Street analysts, signaling a potentially positive outlook for the company's stock. While specific details of the upgrade and the analysts' reasoning are not provided in this snippet, such a shift in sentiment typically suggests that analysts foresee improved financial performance, strategic advantages, or favorable market conditions for HSIC. Investors often view analyst upgrades as a catalyst for stock price appreciation, potentially leading to increased buying interest and upward price momentum.
- 2/24/2026NEUTRALHenry Schein (HSIC) Q4 2025 Earnings Transcript
Investors in Henry Schein Inc. (HSIC) are poised to analyze the Q4 2025 earnings transcript, released on February 24, 2026. This event is pivotal for understanding the financial performance of the company, a global leader in distributing healthcare products and services to medical and dental practices. The report's analysis will provide crucial details on revenues, earnings per share (EPS), operating margins, and future outlook, which are fundamental elements for assessing the company's health and potential growth trajectories. While specific data is not yet available for direct evaluation, the transcript's release marks a key moment for the market, allowing deeper insight into management's statements and responses to analyst questions, thereby shaping expectations for the upcoming fiscal period and its impact on share value.